ACIP Majority Ignores Risks and Recommends Infants Get Merck’s RSV Monoclonal Antibody
On June 25, 2025, the majority of members of the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) ignored risk warnings and voted for a recommendation that infants be given Merck & Co.’s monoclonal antibody, clesrovimab, marketed as Enflonsia. The committee advised using Enflonsia to prevent Respiratory Syncytial Virus […]